Zanubrutinib

Generic Name
Zanubrutinib
Brand Names
Brukinsa
Drug Type
Small Molecule
Chemical Formula
C27H29N5O3
CAS Number
1691249-45-2
Unique Ingredient Identifier
AG9MHG098Z
Background

Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...

Indication

Zanubrutinib is indicated for the treatment of:

Associated Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
Associated Therapies
-
Clinical Trials
Related News

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

First Posted Date
2023-08-07
Last Posted Date
2023-09-14
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
60
Registration Number
NCT05979948
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

First Posted Date
2023-08-04
Last Posted Date
2024-08-02
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
421
Registration Number
NCT05976763
Locations
🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Mercy Hospital Springfield, Springfield, Missouri, United States

🇺🇸

Kalispell Regional Medical Center, Kalispell, Montana, United States

and more 175 locations

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia

First Posted Date
2023-07-19
Last Posted Date
2024-12-06
Lead Sponsor
BeiGene
Target Recruit Count
105
Registration Number
NCT05952037
Locations
🇨🇦

Lions Gate Hospital Chemotherapy Clinic, North Vancouver, British Columbia, Canada

🇨🇦

Qeii Health Science Center, Halifax, Nova Scotia, Canada

🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 69 locations

Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

Phase 2
Recruiting
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
Drug: Zanubrutinib
First Posted Date
2023-06-28
Last Posted Date
2024-04-26
Lead Sponsor
Chen Miao
Target Recruit Count
22
Registration Number
NCT05922839
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

First Posted Date
2023-06-09
Last Posted Date
2023-09-05
Lead Sponsor
Ruijin Hospital
Target Recruit Count
29
Registration Number
NCT05896007
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

First Posted Date
2023-06-06
Last Posted Date
2024-10-31
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
227
Registration Number
NCT05890352
Locations
🇺🇸

SWOG, Portland, Oregon, United States

🇺🇸

Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States

🇺🇸

Saint Joseph Mercy Brighton, Brighton, Michigan, United States

and more 8 locations

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

First Posted Date
2023-06-05
Last Posted Date
2023-07-27
Lead Sponsor
Liaoning Tumor Hospital & Institute
Target Recruit Count
30
Registration Number
NCT05887726
Locations
🇨🇳

Xing Xiaojing, Shenyang, Liaoning, China

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

First Posted Date
2023-05-24
Last Posted Date
2024-03-15
Lead Sponsor
Adam Kittai
Target Recruit Count
24
Registration Number
NCT05873712
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

First Posted Date
2023-04-04
Last Posted Date
2023-04-04
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT05797948
Locations
🇨🇳

the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Zanubrutinib
First Posted Date
2023-03-14
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
58
Registration Number
NCT05767398
Locations
🇺🇸

Fortrea Clinical Research Unit, Dallas, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy